Johnson & Johnson (FRA:JNJ) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JNJ Johnson & Johnson FRA:JNJ
80 GF Score
Price €233.65
GF Value €167.59
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson  (FRA:JNJ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Johnson & Johnson Cyclically Adjusted PB Ratio Related Terms


Johnson & Johnson Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Cyclically Adjusted PB Ratio Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.42 6.50 5.34 5.08 6.38

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 5.59 6.28 7.37 7.71

FRA:JNJ vs ABBV, MRK, LLY: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PB Ratio falls into.


FRA:JNJ
80GF Score
Johnson & Johnson FRA:JNJ
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Johnson & Johnson's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Johnson & Johnson's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=30.861/333.9520*333.9520
=30.861

Current CPI (Jun. 2026) = 333.9520.

Johnson & Johnson Quarterly Data

Book Value per Share CPI Adj_Book
201609 23.784 241.428 32.899
201612 24.667 241.432 34.120
201703 24.404 243.801 33.428
201706 23.484 244.955 32.016
201709 23.306 246.819 31.534
201712 18.676 246.524 25.299
201803 19.176 249.554 25.661
201806 20.081 251.989 26.613
201809 20.737 252.439 27.433
201812 19.633 251.233 26.097
201903 19.771 254.202 25.974
201906 20.203 256.143 26.340
201909 20.294 256.759 26.395
201912 20.126 256.974 26.155
202003 21.221 258.115 27.456
202006 21.301 257.797 27.593
202009 20.888 260.280 26.800
202012 19.645 260.474 25.187
202103 21.276 264.877 26.824
202106 22.292 271.696 27.400
202109 23.033 274.310 28.041
202112 24.760 278.802 29.658
202203 25.536 287.504 29.661
202206 27.781 296.311 31.310
202209 29.099 296.808 32.741
202212 27.535 296.797 30.982
202303 25.105 301.836 27.776
202306 26.956 305.109 29.504
202309 27.948 307.789 30.324
202312 25.865 306.746 28.159
202403 26.938 312.332 28.803
202406 27.733 314.175 29.479
202409 26.113 315.301 27.658
202412 28.684 315.605 30.351
202503 30.059 319.799 31.389
202506 27.776 322.561 28.757
202509 28.040 324.800 28.830
202512 28.834 324.054 29.715
202603 29.279 330.213 29.611
202606 30.861 333.952 30.861

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Johnson & Johnson (FRA:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of €233.65 is trading 39.4% above its estimated GF Value™ of €167.59. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for FRA:JNJ:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €167.59 vs. price of €233.65 (39.4% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the FRA:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
80GF Score

Get the complete analysis for FRA:JNJ

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€233.65
Price
€167.59
GF Value